South Korea · Delayed Price · Currency is KRW AriBioLab Statistics
Total Valuation
AriBioLab has a market cap or net worth of KRW 69.58 billion. The enterprise value is 59.36 billion.
| Market Cap | 69.58B |
| Enterprise Value | 59.36B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
AriBioLab has 26.87 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Current Share Class | 26.87M |
| Shares Outstanding | 26.87M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 1.50% |
| Owned by Institutions (%) | n/a |
| Float | 20.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 209.72 |
| PB Ratio | 7.25 |
| P/TBV Ratio | 7.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.82 |
| EV / Sales | 178.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.59 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.82 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.56 |
| Interest Coverage | -6.50 |
Financial Efficiency
Return on equity (ROE) is -89.44% and return on invested capital (ROIC) is -33.42%.
| Return on Equity (ROE) | -89.44% |
| Return on Assets (ROA) | -25.26% |
| Return on Invested Capital (ROIC) | -33.42% |
| Return on Capital Employed (ROCE) | -118.59% |
| Weighted Average Cost of Capital (WACC) | 6.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.25% in the last 52 weeks. The beta is 0.09, so AriBioLab's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -17.25% |
| 50-Day Moving Average | 3,544.70 |
| 200-Day Moving Average | 2,992.85 |
| Relative Strength Index (RSI) | 39.91 |
| Average Volume (20 Days) | 7,437,136 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AriBioLab had revenue of KRW 331.78 million and -15.54 billion in losses. Loss per share was -578.18.
| Revenue | 331.78M |
| Gross Profit | 304.08M |
| Operating Income | -13.58B |
| Pretax Income | -15.54B |
| Net Income | -15.54B |
| EBITDA | -13.13B |
| EBIT | -13.58B |
| Loss Per Share | -578.18 |
Balance Sheet
The company has 16.13 billion in cash and 5.92 billion in debt, with a net cash position of 10.22 billion or 380.34 per share.
| Cash & Cash Equivalents | 16.13B |
| Total Debt | 5.92B |
| Net Cash | 10.22B |
| Net Cash Per Share | 380.34 |
| Equity (Book Value) | 9.59B |
| Book Value Per Share | 356.21 |
| Working Capital | 8.62B |
Cash Flow
In the last 12 months, operating cash flow was -10.59 billion and capital expenditures -36.10 million, giving a free cash flow of -10.62 billion.
| Operating Cash Flow | -10.59B |
| Capital Expenditures | -36.10M |
| Depreciation & Amortization | 442.47M |
| Net Borrowing | -10.68B |
| Free Cash Flow | -10.62B |
| FCF Per Share | -395.47 |
Margins
| Gross Margin | 91.65% |
| Operating Margin | -4,091.71% |
| Pretax Margin | -4,685.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AriBioLab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.17% |
| Shareholder Yield | -0.17% |
| Earnings Yield | -22.34% |
| FCF Yield | -15.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AriBioLab has an Altman Z-Score of -3.11 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.11 |
| Piotroski F-Score | 1 |